논문검색
Author Cheolwon Suh, Sang Hee Kim, Hyo Jung Kim, Geundoo Jang, Eun Kyung Kim, Ok Bae Ko, Shin Kim, Hee Jung Sohn, Jung Shin Lee, M. Wookun Kim, Jooryung Huh
Place of duty Departments of 1Internal Medicine and 2Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 3Department of Internal Medicine, College of Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea.
Title Prognostic Factors in Non-Hodgkin's Lymphoma Patients Treated by Autologous Stem Cell Transplantation: A Single Center Experience
Publicationinfo Cancer Res Treat. 2005 Oct; 037(05): 294-301.
Key_word Non-Hodgkin\'s lymphoma,Autologous peripheral blood stem cell transplantation,Prognosis,Hematopoietic stem cell mobilization
Full-Text
Abstract Purpose: Autologous stem cell transplantation (ASCT) is increasingly used in patients with non-Hodgkin's lymphoma (NHL). Various clinical parameters-were evaluated to obtain significant predictors of the outcome following ASCT in patients with NHL. Materials and Methods: Between April 1994 and December 2003, ASCT was performed on 80 patients with NHL at the Asan Medical Center. Results: Patients had various histological subtypes and disease status. The two year progression free survival (PFS) and overall survival for all patients were 34 and 31%, respectively. A univariate analysis showed the performance status, stage, modified extranodal involvement category, International Prognostic Index (IPI) at mobilization, disease status at mobilization, and history of radiation prior to mobilization as significant predictors of the outcome following ASCT. Four risk groups, with different 2 year PFS, were identified by the age adjusted IPI at mobilization (mAAIPI): low risk 44%; low intermediate risk 40%; high intermediate risk 19%; and high risk 0% (p=.0003). A multivariate analysis revealed 3 significant factors for the PFS: disease status, prior RT and mAAIPI. Conclusion: The mAAIPI was found to be an independent predictor of the outcome of NHL patients undergoing ASCT. This powerful prognostic tool should be used to evaluate potential candidates for ASCT. (Cancer Res Treat. 2005;37:294-301)